$HIMS 20261120 20.0 PUT$ Conclusion:
Hims & Hers Health (HIMS)
watchlist
has shown highly variable post-earnings trading rather than a dependable bullish pattern. Across 18 reported quarters from 2022Q4 through 2026Q2, the stock rose in 61.1% of first post-report sessions, but only 50.0% of five-session windows ended higher. The five-day average return was +3.51% , yet the median was -1.71% —meaning a handful of large rallies skewed the average upward.
Event-study resultsReturns are measured from the last close before the report to the first and fifth closes in the post-earnings price window.
Historical sample First post-report close Fifth post-report close
Average return, 18 reports +0.77% +3.51%
Median return +1.38% -1.71%
Positive outcomes 11 of 18 (61.1%) 9 of 18 (50.0%)
Best five-day reaction +37.82% —
Worst five-day reaction -16.96% —
Recent earnings reactions
Report Earnings date First post-report close Five-session return
2024Q3 2024-11-04 +1.96% +14.98%
2024Q4 2025-02-24 +4.12% -8.50%
2025Q1 2025-05-05 +2.60% +27.29%
2025Q2 2025-08-04 +1.28% -16.96%
2025Q3 2025-11-03 -2.35% -9.74%
2025Q4 2026-02-23 +3.08% -11.39%
2026Q1 2026-05-11 +0.57% -10.89%
2026Q2 2026-08-10 +0.57% -10.89%
The important takeaway is that an initially benign reaction has often failed to persist. In particular, HIMS had positive first-session reactions in several reports but later sold off over the following week—such as 2025Q2 and 2026Q1/Q2. Conversely, its strongest upside episodes were substantial: +37.82% after 2023Q4 and +27.29% after 2025Q1.
So, for the upcoming 2026Q3 report scheduled after the close on 2026-11-09 , history suggests the key signal is not solely the immediate reaction. The more informative confirmation is whether the move holds through the following several sessions, especially after management guidance and the market’s view of growth durability are absorbed.
Two limitations: this is a relatively small 18-quarter sample, and earnings-window moves can reflect broader market conditions as well as results, guidance, and company-specific news.
Information is for reference only and does not constitute investment advice.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
